Nektar Therapeutics (NKTR) logo

Nektar Therapeutics (NKTR) stock

Immunotherapy medicines , market cap $1.1B

$30.20
-7.19%

Why is NKTR down?

Down 19% over the five sessions to Nov 20 while the S&P 500 fell 9%.

  • Nektar Therapeutics fell 19% in those sessions while biotech stocks fell a median 9%: it trailed its group by 10 points.

Sources: Price history, Nov 20, 2026

−2Long-term trend below a falling 200-day average, down over one year

Tell me next time NKTR moves

Free account, no card. An optional alert when NKTR moves or its score changes.Pro, $1 for a first month. An optional alert when NKTR moves or its score changes.Pro, 7 days free with a card. An optional alert when NKTR moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on NKTR →The other side, how the business stands, the timeline, and its peers, for Pro members.
Quality Score
-10
Poor
In its industry
#267of 273
Checks firing
1of 14
Trending down
From 52-week high
-72.3%
under its best in a year

NKTR's Quality Score rose 1 point on Fri, Nov 20, to -10. More shares traded than usual.

Follow NKTR's trial news. Pro members can get an alert when Nektar Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when NKTR files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEarly 2027“Phase 3 ZENITH AA study to initiate in early 2027”Trial start · SEC filing · Oct 1
Cash$614M, about 9 quarters (2.5 years) at the last year's spendingOn Sep 30 · the company says “into the third quarter of 2028”

Key facts on NKTR

Key facts on NKTR
Since its Dec 2021 highDown 86% sales $101.9M → $52.2M a year
Latest filing10-Q, Nov 13 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$614M, about 9 quarters (2.5 years) at the last year's spendingOn Sep 30 · the company says “into the third quarter of 2028”

NKTR catalysts

Coming up

After its last 4 reports it closed -0.4% on average, higher 2 of 4 times.

4 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for NKTR, and how long its cash lasts

Next step the company has named

Early 2027“Phase 3 ZENITH AA study to initiate in early 2027”Trial start · SEC filing · Oct 1

What it means: when a trial begins, or reaches the stage the company named.

A trial underway
ZENITH AD-1Phase 3 · Recruiting · 510 people · main data estimated May 2028 · NCT07690371

2 more trials, 2 more milestones and 47 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 9 quarters

$614M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into the third quarter of 2028” (8-K, Nov 13).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Nov 12, 2025)
  • At-the-market share sales program (424B5, filed May 8, 2026)

For Pro members: 5 raises and their amounts, and the share count against a year ago.

Insiders

CEO Howard W. Robin sold 429 shares on Nov 17. 11 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Howard Robin’s 18 filings and quotes.

Get an alert when NKTR files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How NKTR ranks in Biotech

NKTR is #267 of 273 by Quality Score.

How NKTR ranks in Biotech
RankStockQuality Score
267Nektar Therapeutics (NKTR) logoNKTRNektar Therapeutics-10

More in Biotech

When does NKTR report earnings, and what happens after?

Expected to report Thu Mar 18, after the close (in 117 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What NKTR reported on Nov 12, 2026

The quarter

Sales of $9.4M, 20% less than a year ago; a loss of $1.63 a share, from $1.87.

“R&D expense increased primarily due to activities to support the Phase 3 ZENITH AD program in atopic dermatitis and the Phase 3 ZENITH AA program in alopecia areata, as well as manufacturing activities”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

NKTR's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

The numbers

Market value
$1.1B
today
Sales
$52.2M
down 16.6% on the year
Free cash flow
-$257M
last 12 months

Sales fell 18% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 5.8% a year over 5 years.

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on NKTR: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-1.8%-3.8%+0.1%
May 7Aug 13Nov 12
ReportedGapReaction5
days
Nov 12, 2026After close-1.2%+0.1%-12.6%
Aug 13, 2026After close-2.5%-3.8%-1.8%
May 7, 2026After close+1.9%-1.8%-10.8%

NKTR closed higher after 2 of its last 4 reports.

All 4 reports, and NKTR's Quality Score going into each

NKTR sales and profit by year

Sales and profit by year

Sales grew in two of the last seven years, to $55.2M in 2025. It made a profit in one of the eight years.

NKTR has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on NKTR, and all 14 on every stock.Get in free →See the top 3 →Start Pro

NKTR RSI on Nov 20: 23.4, below its 50-day and 200-day averages

Not scored

RSI 23.4, MACD below signal, below both averages. Not scored.

The deep dive on NKTR

6 more findings on NKTR, each with its source, for Pro members.

NKTR share count over time

80% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of NKTR outstanding, as filed
Shares
outstanding
As
of
34.2MNov 6, 2026
34.1MAug 7, 2026
33.8MMay 1, 2026
28.7MMar 11, 2026
Offerings, shelves, and splits of NKTR, from its filings
From its
filings
Filed
Set up an at-the-market program for up to $150M of shares, about 13% of its market valueMay 8, 2026
Raised $325M in a sale of shares, about 29% of its market valueApr 23, 2026
Raised $383M in a sale of shares, about 34% of its market valueFeb 13, 2026
Set up an at-the-market program for up to $110M of shares, about 10% of its market valueNov 12, 2025

4 more offerings on file, for Pro members.

NKTR insider trades

2 insiders sold $66K across 4 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellHoward W. Robin$15KPresident & CEOat $35.85 on Nov 17, filed Nov 19

All 4 insider filings on NKTR from the last six months, for Pro members.

All NKTR insider trades

NKTR's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold NKTR?

In ETFs: NKTR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

63 employeesSan Francisco, CAnektar.com

What Nektar Therapeutics says it competes with

“Competition in the pharmaceutical and biotechnology industry is intense and characterized by aggressive research and development and rapidly-evolving science, technology, and standards of medical care throughout the world.”

From its annual report, SEC filing · Mar 13, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on NKTR and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn NKTR's score around: 9 things
  • 13 more filings explained, a plain line each
  • 6 more things pulling NKTR's score down
BreakawayNov 19Howard W. Robin sold NKTR$15K at $35.85, filed Nov 19

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: NKTR's Quality Score is -10 (Poor), #267 of 273 in Biotech. Insiders sold $66K in the last 6 months (Form 4).

What does NKTR's Quality Score say?

NKTR scores -10 today, which Breakaway calls Poor. It is #267 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 19% over the five sessions to Nov 20 while the S&P 500 fell 9%. Cash lasts about 9 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is NKTR's Quality Score?

NKTR scores -10 today, which Breakaway calls Poor (below zero). That is #267 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NKTR's -10.

Are insiders buying NKTR?

2 insiders sold $66K across 4 filings in the last 6 months. No open-⁠market buys on record. The newest is Howard W. Robin, President & CEO, who sold $15K on Nov 17. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Nektar Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.